Xu, Hang; Yan, Zhong-zuo; Guo, Meng-bi; An, Ran; Wang, Xin; Zhang, Rui; Mou, Yan-hua; Hou, Zhuang; Guo, Chun published the artcile< Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections>, Safety of 1-Chloro-2-(chloromethyl)benzene, the main research area is benzylselanyl dichlorophenylethyltriazole preparation antifungal antitumor SAR pharmacokinetics docking; dichlorophenyl phenylselanylethylimidazole preparation antifungal antitumor SAR pharmacokinetics docking; Antifungal; CYP51; Miconazole; Selenium; Superior pharmacological profile.
A series of selenium-containing miconazoles. compounds I, II [R = H, 3-F, 2-Me, etc. ; X= F, Cl], III [R = H, 3-F, 2-Me, etc.; X= F, C] were identified as potent antifungal drugs in our previous study. Representative compound I (MIC = 0.01μg/mL against C.alb. 5314) proved efficacious in inhibiting the growth of fungal pathogens. However, further study showed lead compound I exhibited potential hemolysis, significant cytotoxic effect and unfavorable metabolic stability and was therefore modified to overcome these drawbacks. In this article, the further optimization of selenium-containing miconazole derivatives resulted in the discovery of similarly potent compound II [R = 4-F ; X= F] (MIC = 0.02μg/mL against C.alb. 5314), exhibiting a superior pharmacol. profile with decreased rate of metabolism, cytotoxic effect and hemolysis. Furthermore, compound II [R = 4-F ; X= F] showed fungicidal activity against Candida albicans and significant effects on the treatment of resistant Candida albicans infections. Meanwhile, compound II [R = 4-F ; X= F] not only could reduce the ergosterol biosynthesis pathway by inhibiting CYP51, but also inhibited biofilm formation. More importantly, compound II [R = 4-F ; X= F] also shows promising in vivo efficacy after i.p. injection and the PK study of compound II [R = 4-F ; X= F] was evaluated. In addition, mol. docking studies provide a model for the interaction between the compound II [R = 4-F ; X= F] and the CYP51 protein. Overall, it was believed that these selenium-containing miconazole compounds can be further developed for the potential treatment of fungal infections.
European Journal of Medicinal Chemistry published new progress about Antitumor agents. 611-19-8 belongs to class chlorides-buliding-blocks, and the molecular formula is C7H6Cl2, Safety of 1-Chloro-2-(chloromethyl)benzene.
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics